Takeshi Okanoue

Prof. Takeshi Okanoue

Saiseikai Suita Hospital, Ōsaka, Japan
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
Yoshihiro KamadaYoshihiro Kamada
Yoshihiro Kamada
STShinji Tamura
Shinji Tamura
SKShinichi Kiso
Shinichi Kiso
HMHitoshi Matsumoto
Hitoshi Matsumoto
YSYukiko Saji
Yukiko Saji
YMYuji Matsuzawa
Yuji Matsuzawa

5 January 2012 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YSYoshio Sumida
Yoshio Sumida
MYMasato Yoneda
Masato Yoneda
HHHideyuki Hyogo
Hideyuki Hyogo
YIYoshito Itoh
Yoshito Itoh
MOMasafumi Ono
Masafumi Ono
J(Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
Background: A reliable and inexpensive noninvasive marker of hepatic fibrosis is required in patients with nonalcoholic fatty liver disease (NAFLD). FIB4 index (based on age, aspartate aminotransferase [AST] and alanine aminotransferase [ALT] levels, and platelet counts) is expected to be useful for evaluating hepatic fibrosis. We validated the performance of FIB4 index in a Japanese cohort with NAFLD.Methods: The areas under the receiver operating characteristic curves (AUROC) for FIB4 and six other markers were compared, based on data from 576 biopsy-proven NAFLD patients. Advanced fibrosis was defined as stage 3-4 fibrosis. FIB4 index was assessed as: age (yr) × AST (IU/L)/(platelet count (109/L) × √ALT (IU/L))Results: Advanced fibrosis was found in 64 (11%) patients. The AUROC for FIB4 index was superior to those for the other scoring systems for differentiating between advanced and mild fibrosis. Only 6 of 308 patients with a FIB4 index below the proposed low cut-off point (< 1.45) were under-staged, giving a high negative predictive value of 98%. Twenty-eight of 59 patients with a FIB4 index above the high cut-off point (> 3.25) were over-staged, giving a low positive predictive value of 53%. Using these cutoffs, 91% of the 395 patients with FIB-4 values outside 1.45-3.25 would be correctly classified. Implementation of the FIB4 index in the Japanese population would avoid 58% of liver biopsies.Conclusion: The FIB4 index was superior to other tested noninvasive markers of fibrosis in Japanese patients with NAFLD, with a high negative predictive value for excluding advanced fibrosis. The small number of cases of advanced fibrosis in this cohort meant that this study had limited power for validating the high cut-off point.

16 February 2012 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MYMasato Yoneda
Masato Yoneda
SNShuhei Naka
Shuhei Naka
KNKazuhiko Nakano
Kazuhiko Nakano
KWKoichiro Wada
Koichiro Wada
HEHiroki Endo
Hiroki Endo
Atsushi  NakajimaAtsushi Nakajima
Atsushi Nakajima
Background: Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome that is closely associated with multiple factors such as obesity, hyperlipidemia and type 2 diabetes mellitus. However, other risk factors for the development of NAFLD are unclear. With the association between periodontal disease and the development of systemic diseases receiving increasing attention recently, we conducted this study to investigate the relationship between NAFLD and infection withPorphyromonas gingivalis(P. gingivalis), a major causative agent of periodontitis.Methods: The detection frequencies of periodontal bacteria in oral samples collected from 150 biopsy-proven NAFLD patients (102 with non-alcoholic steatohepatitis (NASH) and 48 with non-alcoholic fatty liver (NAFL) patients) and 60 non-NAFLD control subjects were determined. Detection ofP. gingivalisand other periodontopathic bacteria were detected by PCR assay. In addition, effect ofP. gingivalis-infection on mouse NAFLD model was investigated. To clarify the exact contribution ofP. gingivalis-induced periodontitis, non-surgical periodontal treatments were also undertaken for 3 months in 10 NAFLD patients with periodontitis.Results: The detection frequency ofP. gingivalisin NAFLD patients was significantly higher than that in the non-NAFLD control subjects (46.7% vs. 21.7%, odds ratio: 3.16). In addition, the detection frequency ofP. gingivalisin NASH patients was markedly higher than that in the non-NAFLD subjects (52.0%, odds ratio: 3.91). Most of theP. gingivalisfimbria detected in the NAFLD patients was of invasive genotypes, especially type II (50.0%). Infection of type IIP. gingivalison NAFLD model of mice accelerated the NAFLD progression. The non-surgical periodontal treatments on NAFLD patients carried out for 3 months ameliorated the liver function parameters, such as the serum levels of AST and ALT.Conclusions: Infection with high-virulenceP. gingivalismight be an additional risk factor for the development/progression of NAFLD/NASH.

17 September 2021 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
KTKatsutoshi Tokushige
Katsutoshi Tokushige
KIKenichi Ikejima
Kenichi Ikejima
MOMasafumi Ono
Masafumi Ono
YEYuichiro Eguchi
Yuichiro Eguchi
Yoshihiro KamadaYoshihiro Kamada
Yoshihiro Kamada
KKKazuhiko Koike
Kazuhiko Koike
Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan.

9 June 2021 in Hepatology
Verified
Journal Article
Open access
PDF file
KKKazuhiro Kozumi
Kazuhiro Kozumi
Takahiro KodamaTakahiro Kodama
Takahiro Kodama
HMHiroki Murai
Hiroki Murai
SSSadatsugu Sakane
Sadatsugu Sakane
OGOlivier Govaere
Olivier Govaere
TTTetsuo Takehara
Tetsuo Takehara
Background and Aims: NAFLD is the most common liver disease worldwide. NASH, the progressive form of NAFLD, and advanced fibrosis are associated with poor outcomes. We searched for their noninvasive biomarkers. Approach and Results: Global RNA sequencing of liver tissue from 98 patients with biopsy‐proven NAFLD was performed. Unsupervised hierarchical clustering well distinguished NASH from nonalcoholic fatty liver (NAFL), and patients with NASH exhibited molecular abnormalities reflecting their pathological features. Transcriptomic analysis identified proteins up‐regulated in NASH and/or advanced fibrosis (stage F3‐F4), including matricellular glycoprotein thrombospondin‐2 (TSP‐2), encoded by the thrombospondin 2 (THBS2) gene. The intrahepatic THBS2 expression level showed the highest areas under the receiver operating characteristic curves (AUROCs) of 0.915 and 0.957 for diagnosing NASH and advanced fibrosis, respectively. THBS2 positively correlated with inflammation and ballooning according to NAFLD activity score, serum aspartate aminotransferase and hyaluronic acid (HA) levels, and NAFLD Fibrosis Score (NFS). THBS2 was associated with extracellular matrix and collagen biosynthesis, platelet activation, caspase‐mediated cleavage of cytoskeletal proteins, and immune cell infiltration. Serum TSP‐2 expression was measured in 213 patients with biopsy‐proven NAFLD, was significantly higher in NASH than in NAFL, and increased parallel to fibrosis stage. The AUROCs for predicting NASH and advanced fibrosis were 0.776 and 0.856, respectively, which were comparable to Fibrosis‐4 index, serum HA level, and NFS in advanced fibrosis diagnosis. Serum TSP‐2 level and platelet count were independent predictors of NASH and advanced fibrosis. Serum TSP‐2 levels could stratify patients with NAFLD according to the risk of hepatic complications, including liver cancer and decompensated cirrhotic events. Conclusions: TSP‐2 may be a useful biomarker for NASH and advanced fibrosis diagnosis in patients with NAFLD.

24 July 2010 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
HPHyohun Park
Hyohun Park
TSToshihide Shima
Toshihide Shima
KYKanji Yamaguchi
Kanji Yamaguchi
HMHironori Mitsuyoshi
Hironori Mitsuyoshi
MMMasahito Minami
Masahito Minami
TOTakeshi Okanoue
Takeshi Okanoue